Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | IGF1R | P08069 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 3/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | CDK7 | P50613 | 7/20 | 0.46 |
| ▸ | CCNH | P51946 | 7/20 | 0.46 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.43 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30221690 | 0.91 | EGFR (0.62) | EGFRKCNH2IGF1RCDK1KDR | |
| SCHEMBL24900456 | 0.91 | EGFR (0.62) | EGFRKCNH2IGF1RCDK1KDR | |
| SCHEMBL24900791 | 0.90 | EGFR (0.49) | EGFRKCNH2IGF1RCDK1KDR | |
| SCHEMBL30221522 | 0.90 | EGFR (0.49) | EGFRKCNH2IGF1RCDK1KDR | |
| SCHEMBL24900508 | 0.89 | CDK1 (0.53) | EGFRKCNH2IGF1RCDK1KDR | |
| SCHEMBL30221482 | 0.89 | CDK1 (0.53) | EGFRKCNH2IGF1RCDK1KDR | |
| SCHEMBL24900465 | 0.83 | EGFR (0.68) | EGFRKCNH2IGF1R | |
| SCHEMBL31503148 | 0.82 | EGFR (0.54) | EGFRKCNH2IGF1R | |
| SCHEMBL24900457 | 0.82 | EGFR (0.54) | EGFRKCNH2IGF1R | |
| SCHEMBL24900802 | 0.80 | EGFR (0.65) | EGFRKCNH2IGF1RCDK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | ACEA Therapeutics, Inc. (US) | 2025-05-01 | — | — | US | disclosed |
| WO-2023287783-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023287783-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136576-A1 | Heterocyclic Compounds and Uses Thereof | CHEK2, CDK2, CDK1 | EGFR 623/4885KCNH2 4555/4885IGF1R 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.